Yamaoka Kunihiro
Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan.
Clin Calcium. 2018;28(5):678-685.
Janus kinase(JAK)inhibitor is a new orally available disease modifying anti-rheumatic drug that has shown anti-rheumatic effect resembling biologics. Clinical trials for autoinflammatory and autoimmune diseases are under investigation. Administration route is convenient compared to biologics and possess high anti-rheumatic effect, however specific side effects considered as a class-effect exists. I would like to offer the best conceivable practice with JAK inhibitors based on evidence from clinical trials and real world experiences.
Janus激酶(JAK)抑制剂是一种新型口服疾病改善抗风湿药物,已显示出类似生物制剂的抗风湿效果。针对自身炎症性和自身免疫性疾病的临床试验正在进行中。与生物制剂相比,给药途径方便且具有较高的抗风湿效果,但存在被视为类效应的特定副作用。我想根据临床试验和真实世界经验提供关于JAK抑制剂的最佳可行实践。